tetano
Editor, Senior Moderator
J Med Virol. 2018 May 2. doi: 10.1002/jmv.25212. [Epub ahead of print]
[h=1]Treatment with broadly neutralizing influenza antibodies reduces severity of secondary pneumococcal pneumonia in mice.[/h] van Someren Gr?ve F[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], van der Sluijs KF[SUP]2[/SUP], Tuip AM[SUP]2[/SUP], Schultz MJ[SUP]1,[/SUP][SUP]2,[/SUP][SUP]4[/SUP], de Jong MD[SUP]3[/SUP], Juffermans NP[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Secondary bacterial pneumonia is a frequent complication of influenza, associated with high morbidity and mortality. We hypothesized that treatment with neutralizing influenza A antibody AT10_002 protects against severe secondary pneumococcal infection in a mouse model of influenza A infection.
[h=4]METHODS:[/h] Influenza A (H3N2) virus-infected male C57Bl6 mice were treated intravenously with either AT10_002 or a control two days post-infection. Seven days later both groups were infected with Streptococcus pneumoniae, and sacrificed 18 hours later.
[h=4]RESULTS:[/h] Mice receiving AT10_002 showed less loss of bodyweight compared to controls (+1% vs. -12%, P <0.001), lower viral loads in bronchoalveolar lavage fluids (BALF) (7 versus 194 RNA copies/?l, P <0.001), and reduced bacterial outgrowth in lung homogenates (3.3?10^1 versus 2.5?10^5 colony forming units/mg, P <0.001). The treatment group showed lower pulmonary wet weights, lower cell counts and lower protein levels in BALF compared to controls. Treatment with AT10_002 was associated with lower levels of TNF-α, IL-6, KC and IFN-γ in BALF, and lower IL-6 and KC in lung homogenates.
[h=4]CONCLUSIONS:[/h] Treatment with anti-influenza antibody AT10_002 is associated with reduced weight loss, viral load, bacterial outgrowth and lung injury in a murine model of secondary pneumococcal pneumonia following influenza infection. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] AT10_002; S. pneumoniae; broadly neutralizing antibodies; influenza virus; murine model; secondary infections
PMID: 29718555 DOI: 10.1002/jmv.25212
[h=1]Treatment with broadly neutralizing influenza antibodies reduces severity of secondary pneumococcal pneumonia in mice.[/h] van Someren Gr?ve F[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], van der Sluijs KF[SUP]2[/SUP], Tuip AM[SUP]2[/SUP], Schultz MJ[SUP]1,[/SUP][SUP]2,[/SUP][SUP]4[/SUP], de Jong MD[SUP]3[/SUP], Juffermans NP[SUP]1,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Secondary bacterial pneumonia is a frequent complication of influenza, associated with high morbidity and mortality. We hypothesized that treatment with neutralizing influenza A antibody AT10_002 protects against severe secondary pneumococcal infection in a mouse model of influenza A infection.
[h=4]METHODS:[/h] Influenza A (H3N2) virus-infected male C57Bl6 mice were treated intravenously with either AT10_002 or a control two days post-infection. Seven days later both groups were infected with Streptococcus pneumoniae, and sacrificed 18 hours later.
[h=4]RESULTS:[/h] Mice receiving AT10_002 showed less loss of bodyweight compared to controls (+1% vs. -12%, P <0.001), lower viral loads in bronchoalveolar lavage fluids (BALF) (7 versus 194 RNA copies/?l, P <0.001), and reduced bacterial outgrowth in lung homogenates (3.3?10^1 versus 2.5?10^5 colony forming units/mg, P <0.001). The treatment group showed lower pulmonary wet weights, lower cell counts and lower protein levels in BALF compared to controls. Treatment with AT10_002 was associated with lower levels of TNF-α, IL-6, KC and IFN-γ in BALF, and lower IL-6 and KC in lung homogenates.
[h=4]CONCLUSIONS:[/h] Treatment with anti-influenza antibody AT10_002 is associated with reduced weight loss, viral load, bacterial outgrowth and lung injury in a murine model of secondary pneumococcal pneumonia following influenza infection. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] AT10_002; S. pneumoniae; broadly neutralizing antibodies; influenza virus; murine model; secondary infections
PMID: 29718555 DOI: 10.1002/jmv.25212